Babson Diagnostics Plans To Deliver What Theranos Could Not
Babson recently raised $31m to accelerate commercialization of its blood testing “ecosystem,” developed with help from Siemens Healthineers and Becton Dickinson.
You may also be interested in...
In this roundup feature focusing on the developments in digital health, we highlight the key news and announcements from July.
Medtech Insight has spoken to several companies aiming to release devices that will replace current blood glucose monitors via disruptive, innovative technologies.
In another blow from the US government, securities regulators have severely penalized Theranos and its cofounder, Elizabeth Holmes, for allegedly lying to investors to raise funds.